# Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

> **NCT03710824** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 180 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03710824
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710824, "Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03710824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*